NCT04210180View on ClinicalTrials.gov

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

October 14, 2020

Study Completion Date

March 22, 2021

Conditions
Smoking CessationHarm Reduction
Interventions
DRUG

Varenicline

0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.

OTHER

e-cigarette

Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.

Trial Locations (2)

27617

Rose Research Center, Raleigh

28262

Rose Research Center, Charlotte

All Listed Sponsors
collaborator

Foundation for a Smoke Free World INC

OTHER

lead

Rose Research Center, LLC

INDUSTRY

NCT04210180 - Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction | Biotech Hunter | Biotech Hunter